Invivyd's SPEAR Study recommends VYD2311 for Long COVID treatment.

Invivyd announced that the SPEAR Study Group has recommended a clinical study to evaluate the effects of monoclonal antibody therapy on Long COVID. The study will focus on VYD2311, a promising next-generation candidate, and aims to decrease circulating spike protein in eligible patients and explore potential clinical benefits. The study design contemplates maintaining high antiviral antibody titers to suppress underlying chronic infection that may drive Long COVID pathology.

Invivyd, Inc. has made significant strides in the development of monoclonal antibodies as a potential alternative to traditional vaccines for COVID-19 prevention. The Waltham, Massachusetts-based company recently announced that the SPEAR Study Group has recommended a clinical study to evaluate the effects of monoclonal antibody therapy on Long COVID. The study will focus on VYD2311, a promising next-generation candidate developed by Invivyd, and aims to decrease circulating spike protein in eligible patients and explore potential clinical benefits.

The study design contemplates maintaining high antiviral antibody titers over an extended period to maximally suppress underlying chronic infection that may drive Long COVID pathology. Drs. Amy Proal and David Putrino, representing the SPEAR Study Group, will present the proposed study design for consideration at the Second Annual RECOVER-TLC Workshop, scheduled for September 9-10, 2025.

VYD2311, which has around 99% structural similarity to Invivyd's pemivibart, has shown promising results in early clinical trials. The company expects both Pemgarda and VYD2311 to maintain their antiviral activity against new SARS-CoV-2 lineages, including the currently dominant Stratus variant. However, the efficacy of VYD2311 in treating Long COVID remains to be seen.

The SPEAR Study Group's recommendation is a significant step forward for Invivyd, positioning the company at the forefront of research into Long COVID treatments. The study, if successful, could pave the way for the approval of VYD2311 as a therapeutic option for individuals suffering from Long COVID or Post-Vaccination Syndrome (PVS).

Invivyd's stock has seen a positive reaction to the news, with investors expressing confidence in the company's ability to deliver on its promise of innovative COVID-19 treatments. The company's focus on monoclonal antibodies, which provide passive immunity, could offer a viable alternative to vaccines for high-risk individuals, particularly those with compromised immune systems.

References:
[1] https://cen.acs.org/pharmaceuticals/biologics/Monoclonal-antibody-maker-sees-opportunity/103/web/2025/09
[2] https://www.globenewswire.com/news-release/2025/09/04/3144345/0/en/SPEAR-Study-Group-to-Present-its-Recommended-Long-COVID-Antibody-Study-Design-Featuring-Invivyd-s-VYD2311-At-RECOVER-TLC-Workshop-September-9-10-2025.html